Experimental approaches for the treatment of malignant gliomas

被引：73

作者：

Arko, Leopold ^{[1
,2
,3
]}

Katsyv, Igor ^{[1
]}

Park, Grace E. ^{[4
]}

Luan, William Patrick ^{[1
]}

Park, John K. ^{[1
]}

机构：

[1] NINDS, Surg & Mol Neurooncol Unit, NIH, Bethesda, MD 20892 USA

[2] NIH, Howard Hughes Med Inst, Res Scholars Program, Bethesda, MD 20892 USA

[3] Univ New Mexico Sch Med, Albuquerque, NM USA

[4] NIAMSD, NIH, Bethesda, MD 20892 USA

来源：

PHARMACOLOGY & THERAPEUTICS | 2010年 / 128卷 / 01期

基金：

美国国家卫生研究院;

关键词：

Malignant glioma; Glioblastoma; Anaplastic astrocytoma; Chemotherapy; Biologic therapy; Immunotherapy; Clinical trial; GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; TYROSINE KINASE INHIBITOR; NEWLY-DIAGNOSED GLIOBLASTOMA; ACTIVATED KILLER-CELLS; HIGH-GRADE GLIOMA; BRAIN-TUMOR CONSORTIUM; LONG-TERM SURVIVAL; BETA GENE-THERAPY; CONVECTION-ENHANCED DELIVERY;

D O I：

10.1016/j.pharmthera.2010.04.015

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Malignant gliomas, which include glioblastomas and anaplastic astrocytomas, are the most common primary tumors of the brain. Over the past 30 years, the standard treatment for these tumors has evolved to include maximal safe surgical resection, radiation therapy and temozolomide chemotherapy. While the median survival of patients with glioblastomas has improved from 6 months to 14.6 months, these tumors continue to be lethal for the vast majority of patients. There has, however, been recent substantial progress in our mechanistic understanding of tumor development and growth. The translation of these genetic, epigenetic and biochemical findings into therapies that have been tested in clinical trials is the subject of this review. Published by Elsevier Inc.

引用

页码：1 / 36

页数：36

共 452 条

[1]

Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis [J].

Abounader, R ;

Laterra, J .

NEURO-ONCOLOGY, 2005, 7 (04) :436-451

[2]

Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16 [J].

Aghi, M. ;

Visted, T. ;

DePinho, R. A. ;

Chiocca, E. A. .

ONCOGENE, 2008, 27 (30) :4249-4254

[3]

Replicative adenoviruses for cancer therapy [J].

Alemany, R ;

Balagué, C ;

Curiel, DT .

NATURE BIOTECHNOLOGY, 2000, 18 (07) :723-727

[4]

Allen C, 2008, EXPERT OPIN BIOL TH, V8, P213, DOI [10.1517/14712598.8.2.213, 10.1517/14712598.8.2.213 ]

[5]

Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter [J].

Alonso, Marta M. ;

Gomez-Manzano, Candelaria ;

Bekele, B. Nebiyou ;

Yung, W. K. Alfred ;

Fueyo, Juan .

CANCER RESEARCH, 2007, 67 (24) :11499-11504

[6]

High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus [J].

Anderson, BD ;

Nakamura, T ;

Russell, SJ ;

Peng, KW .

CANCER RESEARCH, 2004, 64 (14) :4919-4926

[7]

ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis [J].

Anderson, Joshua C. ;

Grammer, J. Robert ;

Wang, Wenquan ;

Nabors, L. Burton ;

Henkin, Jack ;

Stewart, Jerry E., Jr. ;

Gladson, Candece L. .

CANCER BIOLOGY & THERAPY, 2007, 6 (03) :454-462

[8]

[Anonymous], J CLIN ONCOL

[9]

Molecularly Targeted Therapies for Malignant Gliomas [J].

Argyriou, Andreas A. ;

Kalofonos, Haralabos P. .

MOLECULAR MEDICINE, 2009, 15 (3-4) :115-122

[10]

INTRATUMORAL LAK CELL AND INTERLEUKIN-2 THERAPY OF HUMAN GLIOMAS [J].

BARBA, D ;

SARIS, SC ;

HOLDER, C ;

ROSENBERG, SA ;

OLDFIELD, EH .

JOURNAL OF NEUROSURGERY, 1989, 70 (02) :175-182

← 1 2 3 4 5 6 7 8 9 10 →